Key facts
- This page summarizes Jason O'Byrne's Form 4 filing for Caribou Biosciences, Inc. (CRBU).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 22 Feb 2024, 17:28.
Jason O'Byrne - 20 Feb 2024 Form 4 Insider Report for Caribou Biosciences, Inc. (CRBU)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- CRBU
- Reported as of
- 20 Feb 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 Feb 2024, 17:28:33 UTC
- Prior SEC filing
- 23 Feb 2023
- Next SEC filing
- 03 Oct 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Barbara G. McClung, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jason O'Byrne filed Form 4 for Caribou Biosciences, Inc. (CRBU) on 22 Feb 2024.
Change
- Previous filing in this sequence was filed on 23 Feb 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CRBU
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +33,000
- Change %
- +126%
- Price
- $0.000000
- Shares after
- 59,224
- Date
- 20 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CRBU
transaction
Derivative
Option to purchase Common Stock
Award
- Transaction value
- $0
- Shares
- +153,000
- Change %
- Price
- $0.000000
- Shares after
- 153,000
- Date
- 20 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 153,000
- Exercise price
- $6.81
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2025, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date.
Footnote F2
Includes 1,888 shares purchased pursuant to the Issuer's 2021 Employee Stock Purchase Plan on February 15, 2022 for $9.85 per share.
Footnote F3
25% of the options will vest upon the one-year anniversary of the grant date, February 20, 2025, and 1/48th will vest monthly thereafter over the 36-month period following the one-year cliff, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.